← back to search

Calvin Yeang

University of California San Diego · US
Area of research
Surgery · Immunology
Research interest
Research interests include Lipoproteins and Cardiovascular Health, Atherosclerosis and Cardiovascular Diseases, Cancer, Lipids, and Metabolism, and Diabetes, Cardiovascular Risks, and Lipoproteins.
h-index
30
citations
4,661
works
100
NIH funding
primary concept
email

Recent publications

<b>AHA PREVENT Equations and Lipoprotein(a) for Cardiovascular Disease Risk </b>
JAMA Cardiology 2025cited by 22position: middledoi
The effects of colchicine on lipoprotein(a)- and oxidized phospholipid-associated cardiovascular disease risk
European Journal of Preventive Cardiology 2024cited by 20position: middledoi
Lipoprotein(a) Testing Trends in a Large Academic Health System in the United States
Journal of the American Heart Association 2023cited by 113position: lastdoi
Lipoprotein(a) and carotid intima-media thickness in children with familial hypercholesterolaemia in the Netherlands: a 20-year follow-up study
The Lancet Diabetes & Endocrinology 2023cited by 43position: middledoi
Lipoprotein(a) and the pooled cohort equations for ASCVD risk prediction: The Multi-Ethnic Study of Atherosclerosis
Atherosclerosis 2023cited by 23position: middledoi
Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol
Journal of the American College of Cardiology 2022cited by 196position: firstdoi
DNA methyltransferase 3 alpha and TET methylcytosine dioxygenase 2 restrain mitochondrial DNA-mediated interferon signaling in macrophages
Immunity 2022cited by 100position: middledoi
Novel method for quantification of lipoprotein(a)-cholesterol: implications for improving accuracy of LDL-C measurements
Journal of Lipid Research 2021cited by 109position: firstdoi
Clonal hematopoiesis driven by DNMT3A and TET2 mutations: role in monocyte and macrophage biology and atherosclerotic cardiovascular disease
Current Opinion in Hematology 2021cited by 63position: lastdoi
Atherogenic Lipoprotein(a) Increases Vascular Glycolysis, Thereby Facilitating Inflammation and Leukocyte Extravasation
Circulation Research 2020cited by 193position: middledoi
Low‐Density Lipoprotein Cholesterol Corrected for Lipoprotein(a) Cholesterol, Risk Thresholds, and Cardiovascular Events
Journal of the American Heart Association 2020cited by 62position: middledoi
ApoCIII-Lp(a) complexes in conjunction with Lp(a)-OxPL predict rapid progression of aortic stenosis
Heart 2020cited by 40position: middledoi
Statin therapy increases lipoprotein(a) levels
European Heart Journal 2019cited by 489position: middledoi
Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis
Journal of Lipid Research 2019cited by 64position: middledoi
Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice
Nature 2018cited by 513position: middledoi
Association of Mild to Moderate Aortic Valve Stenosis Progression With Higher Lipoprotein(a) and Oxidized Phospholipid Levels
JAMA Cardiology 2018cited by 107position: middledoi
Reduction of myocardial ischaemia–reperfusion injury by inactivating oxidized phospholipids
Cardiovascular Research 2018cited by 88position: firstdoi
Relationship between “LDL-C”, estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide
Journal of clinical lipidology 2018cited by 62position: middledoi
Lipoprotein(a)-Associated Molecules Are Prominent Components in Plasma and Valve Leaflets in Calcific Aortic Valve Stenosis
JACC Basic to Translational Science 2017cited by 85position: middledoi
Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans
Circulation 2016cited by 640position: middledoi
Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a)
Journal of clinical lipidology 2016cited by 109position: firstdoi
PCSK9 Association With Lipoprotein(a)
Circulation Research 2016cited by 108position: middledoi
Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis
Current Opinion in Cardiology 2016cited by 80position: firstdoi
Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis
Journal of the American College of Cardiology 2015cited by 393position: middledoi
‘LDL-C’ = LDL-C + Lp(a)-C
Current Opinion in Lipidology 2015cited by 150position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Sotirios Tsimikas · Vanderbilt University Medical Center22 papers (2015–2025)Joseph L. Witztum · Optimum Therapeutics (United States)14 papers (2015–2022)Xiaohong Yang · University of California San Diego5 papers (2015–2020)Philippe Pîbarot · Emory University3 papers (2015–2020)Romain Capoulade · Délégation Régionale Grand Ouest3 papers (2015–2020)Christopher K. Glass · University of California San Diego3 papers (2018–2022)Ming‐Yow Hung · Taipei Medical University3 papers (2016–2018)Shuting Xia · Hesco (United States)3 papers (2018–2022)Amir Ravandi · St. Boniface Hospital3 papers (2016–2018)Marlys L. Koschinsky · Czech Academy of Sciences, Institute of Psychology3 papers (2016–2020)Jeffrey Kroon · Resverlogix (Canada)3 papers (2016–2023)Harpreet Bhatia · Emory University3 papers (2023–2025)Jean G. Dumesnil · Université Laval2 papers (2015–2020)Andrea L. Edel · University of Manitoba2 papers (2017–2018)Kirk L. Peterson · University of California San Diego2 papers (2018–2018) · 2 papers (2015–2018)Nicholas J. Viney · Ionis Pharmaceuticals (United States)2 papers (2018–2019)Koen H.M. Prange · Amsterdam University Medical Centers2 papers (2020–2022)Jean‐Pierre Després · Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-Saint-Jean2 papers (2015–2020) · 2 papers (2017–2020)